Key Insights

Highlights

Success Rate

83% trial completion

Published Results

167 trials with published results (21%)

Research Maturity

397 completed trials (50% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

10.6%

84 terminated out of 795 trials

Success Rate

82.5%

-4.0% vs benchmark

Late-Stage Pipeline

11%

89 trials in Phase 3/4

Results Transparency

42%

167 of 397 completed with results

Key Signals

167 with results83% success84 terminated

Data Visualizations

Phase Distribution

580Total
Not Applicable (198)
Early P 1 (14)
P 1 (132)
P 2 (147)
P 3 (65)
P 4 (24)

Trial Status

Completed397
Recruiting131
Terminated84
Unknown61
Active Not Recruiting54
Withdrawn30

Trial Success Rate

82.5%

Benchmark: 86.5%

Based on 397 completed trials

Clinical Trials (795)

Showing 20 of 20 trials
NCT04774536Phase 1RecruitingPrimary

Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

NCT05170412RecruitingPrimary

Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

NCT05075824Phase 2CompletedPrimary

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)

NCT07247188Phase 3RecruitingPrimary

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

NCT07392216RecruitingPrimary

Functional Ovarian Reserve in Sickle Cell Disease

NCT03937817Recruiting

Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

NCT00011648Completed

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

NCT03720626UnknownPrimary

Managed Access Programs for SEG101, Crizanlizumab

NCT07401823Phase 2Enrolling By InvitationPrimary

Open-Label Extension Study to Pioneer Study 6058-SCD-101

NCT06635902Phase 2RecruitingPrimary

Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

NCT05143021Active Not RecruitingPrimary

Sickle Cell Disease Obstetric Multi-Disciplinary Care Programme

NCT06975865Phase 3RecruitingPrimary

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

NCT06016634Phase 2RecruitingPrimary

Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

NCT06880679Not ApplicableRecruiting

Ultrasound Acute Chest Syndrome Sickle Cell Disease

NCT05662098Early Phase 1Active Not RecruitingPrimary

Alternative Dosing And Prevention of Transfusions (ADAPT)

NCT07155031Phase 2WithdrawnPrimary

Biotin-Acridine Red Cell Exchange Kinetics

NCT04417673Completed

Living With Sickle Cell Disease in the COVID-19 Pandemic

NCT05736419Phase 2RecruitingPrimary

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT00047996Enrolling By InvitationPrimary

Blood Collection for Research Related to Certain Diseases Involving Blood Vessels

NCT05725902Phase 2CompletedPrimary

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

Scroll to load more

Research Network

Activity Timeline